S. Landis, Clara C. Chen, J. Byrne, Stephen J. Jones, R. Dhanda, J. Nelson
{"title":"医生对拉帕替尼治疗患者肝功能检测监测指导的依从性评估","authors":"S. Landis, Clara C. Chen, J. Byrne, Stephen J. Jones, R. Dhanda, J. Nelson","doi":"10.12788/J.CMONC.0057","DOIUrl":null,"url":null,"abstract":"Methods A retrospective observational cohort study comprising 396 women with HER2 metastatic breast cancer who initiated lapatinib between March 1, 2007 and June 30, 2010. Data were captured from electronic medical records (EMR) of communitybased oncology practices. Patients were categorized by whether they initiated lapatinib before or after the label change; LFT monitoring was evaluated using a preversus post-label study design. We measured the proportion of patients who had LFTs within 30 days before lapatinib initiation, LFTs during each 6-week period of treatment, and lapatinib permanently withdrawn after experiencing an extreme LFT elevation.","PeriodicalId":72649,"journal":{"name":"Community oncology","volume":"10 1","pages":"258-265"},"PeriodicalIF":0.0000,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Assessment of physician compliance to liver function test monitoring guidance for patients treated with lapatinib\",\"authors\":\"S. Landis, Clara C. Chen, J. Byrne, Stephen J. Jones, R. Dhanda, J. Nelson\",\"doi\":\"10.12788/J.CMONC.0057\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Methods A retrospective observational cohort study comprising 396 women with HER2 metastatic breast cancer who initiated lapatinib between March 1, 2007 and June 30, 2010. Data were captured from electronic medical records (EMR) of communitybased oncology practices. Patients were categorized by whether they initiated lapatinib before or after the label change; LFT monitoring was evaluated using a preversus post-label study design. We measured the proportion of patients who had LFTs within 30 days before lapatinib initiation, LFTs during each 6-week period of treatment, and lapatinib permanently withdrawn after experiencing an extreme LFT elevation.\",\"PeriodicalId\":72649,\"journal\":{\"name\":\"Community oncology\",\"volume\":\"10 1\",\"pages\":\"258-265\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Community oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12788/J.CMONC.0057\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Community oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/J.CMONC.0057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Assessment of physician compliance to liver function test monitoring guidance for patients treated with lapatinib
Methods A retrospective observational cohort study comprising 396 women with HER2 metastatic breast cancer who initiated lapatinib between March 1, 2007 and June 30, 2010. Data were captured from electronic medical records (EMR) of communitybased oncology practices. Patients were categorized by whether they initiated lapatinib before or after the label change; LFT monitoring was evaluated using a preversus post-label study design. We measured the proportion of patients who had LFTs within 30 days before lapatinib initiation, LFTs during each 6-week period of treatment, and lapatinib permanently withdrawn after experiencing an extreme LFT elevation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
